Kiniksa Pharmaceuticals Analyst Ratings
Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $39
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35
Kiniksa Pharmaceuticals Analyst Ratings
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32
Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $34 From $30, Maintains Outperform Rating
Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution
Kiniksa Pharmaceuticals (KNSA) Receives a Buy From Goldman Sachs
Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Rhythm Pharmaceuticals (RYTM) and Kiniksa Pharmaceuticals (KNSA)
Strong Arcalyst Sales and Promising Pipeline Reinforce Kiniksa Pharmaceuticals Buy Rating
Kiniksa Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and UnitedHealth (UNH)